Talk:Oncolytic virus

message: [http://www.nbglobe.com/2010/11/19/status-on-oncolytic-virus-therapies-for-pediatric-solid-tumors/ Status on oncolytic virus therapies for pediatric solid tumors -
A review of a new therapy for neuroblastoma] summarises history, adult work and current pediatric trials. Can we use this source (it gives references) in the article even though it seems to be a blog ? Rod57 (talk) 20:58, 25 November 2010 (UTC)
replies: text: Should be alright for uncontroversial information. They seemed to have sourced most of the info from this 2010 review. It would be better to cite that, although don't take the blogs word for it (drop me a line on my talk page if you can't access it). Also a quick NCBI search turned up this which is free and may also be useful. AIRcorn (talk) 04:45, 26 November 2010 (UTC)
thread_title:  Review of pediatric use 

message: JX-954 and/or JX-594?  99.190.82.45 (talk) 02:11, 5 September 2011 (UTC)
replies: text: JX-594 is now mentioned under clinical research/Phase II. - Rod57 (talk) 02:46, 5 February 2016 (UTC)
thread_title:  JX-954 and/or JX-594 

message: also where T-VEC is mentioned in the new section on Approved agents - detail is out of date - Rod57 (talk) 02:20, 5 February 2016 (UTC)
thread_title:  Intro needs updating now T-VEC is approved 

message: Are subsections suppressed somewhere - it would be useful to show them. - Rod57 (talk) 02:45, 5 February 2016 (UTC)
thread_title:  The automatic contents list is not showing subsections 

message: The section below seems entirely built by people going into clinicaltrials.gov and "reporting" on what is there. 
This is not what we do in WP.  Somebody can do this on their blog perhaps... The "lead" sentence is ridiculous in talking about the period  from 2014-2018 and having a ref from 2016 (actually accepted in Nov 2015)
The more specific section below the table, is also done in the spirit of trying to provide "news" with language about some  trial "ongoing" or "has started", all with no dates.  One big WP:RELTIME ball of confusion.   A bunch of raw spam "sources" as well.   None of this is appropriate to the mission, as  it is  written.  
;Clinical research==
In 2014-2018 period a number of clinical trials were initiated for a wide range of oncolytic virus products, reflecting the ongoing clinical development of this class of therapy.
Agent                     	Indication               	Phase 	Status                 	Route                          	Notes                                                                     	Ref
Ad5-yCD/mutTKSR39rep-hIL12	Prostate carcinoma       	I     	Recruiting             	Intraprostatic                 	As single agent                                                           	NCT02555397
Cavatak™                  	Bladder carcinoma        	I     	Recruiting             	Intravesical                   	Optionally combined with low-dose mitomycin C                             	NCT02316171
                          	Melanoma                 	I     	Recruiting             	Intratumoral                   	Combined with ipilimumab                                                  	NCT02307149
                          	                         	      	                       	                               	Combined with pembrolizumab                                               	NCT02565992
CG0070                    	Bladder carcinoma        	II    	No longer available    	Intravesical                   	As single agent                                                           	NCT02143804
                          	                         	      	Recruiting             	Intravesical                   	As single agent                                                           	NCT02365818
DNX-2401                  	Brain tumors             	I     	Recruiting             	Intratumoral                   	Combined with IFNγ                                                        	NCT02197169
G207                      	Brain tumors             	I     	Not yet recruiting     	Intratumoral                   	Optionally combined with radiation therapy                                	NCT02457845
GL-ONC1                   	Ovarian cancer           	II    	Recruiting             	Intraperitoneal                	As single agent                                                           	NCT02759588
HF10                      	Melanoma                 	II    	Recruiting             	Intratumoral                   	Combined with ipilimumab                                                  	NCT02272855
                          	Solid tumors             	I     	Recruiting             	Intratumoral                   	As single agent                                                           	NCT02428036
Imlygic®                  	Hepatocellular carcinoma 	I     	Not yet recruiting     	Intratumoral                   	As single agent                                                           	NCT02509507
                          	Melanoma                 	n.a.  	Enrolling by invitation	Intratumoral                   	As single agent                                                           	NCT02173171
                          	                         	II    	Recruiting             	Intratumoral                   	As single agent                                                           	NCT02366195
                          	                         	      	                       	                               	Combined with surgery                                                     	NCT02211131
                          	                         	III   	Active, not recruiting 	Intratumoral                   	Combined with pembrolizumab                                               	NCT02263508
                          	                         	      	Available              	Intratumoral                   	As single agent                                                           	NCT02147951
                          	                         	      	                       	                               	                                                                          	NCT02297529
                          	Soft tissue sarcoma      	I/II  	Recruiting             	Intratumoral                   	Combined with radiotherapy                                                	NCT02453191
JX-594                    	Hepatocellular carcinoma 	III   	Recruiting             	Intratumoral and Intraveinously	Combined with sorafenib                                                   	NCT02562755
                          	Solid Tumors             	II    	Recruiting             	Intratumoral and intraveinously	Combined with metronomic cyclophosphamide                                 	NCT02630368
                          	Renal Cell Carcinoma 2L  	I     	Recruiting             	Intratumoral and intraveinously	Combined with REGN2810                                                    	
                          	Colorectal Cancer 2L/3L  	I     	Recruiting             	Intratumoral and intraveinously	Combined with PD-L1 and CTLA4                                             	
                          	Liver Cancer             	I     	Recruiting             	Intratumoral and intraveinously	Combined with Nivolumab                                                   	NCT03071094
                          	Solid Tumors             	I     	Recruiting             	Intratumoral and intraveinously	Combined with Ipilimumab                                                  	NCT02977156
                          	Solid Tumors(neoadjuvant)	I     	Recruiting             	Intratumoral and intraveinously	Monotherapy                                                               	
                          	Liver Cancer             	I     	Recruiting             	Intratumoral and intraveinously	Combined with PD-L1                                                       	
MG1-MA3                   	Solid tumors             	I/II  	Recruiting             	Intravenous                    	Combined with a MAGEA3-encoding adenovirus                                	NCT02285816
MV-NIS                    	Gynecological tumors     	II    	Recruiting             	Intraperitoneal                	As single agent                                                           	NCT02364713
                          	Multiple myeloma         	II    	Recruiting             	Intravenous                    	Combined with cyclophosphamide                                            	NCT02192775
OBP-301                   	Solid tumors             	I     	Not yet recruiting     	Intratumoral                   	As single agent                                                           	NCT02293850
Reolysin                  	Brain tumors             	I     	Recruiting             	Intravenous                    	Combined with GM-CSF s.c.                                            	NCT02444546
                          	Multiple myeloma         	I     	Recruiting             	Intravenous                    	Combined with dexamethasone plus a proteasomal inhibitor                  	NCT02101944
                          	                         	      	                       	                               	                                                                          	NCT02514382
Toca 511                  	Brain tumors             	II/III	Not yet recruiting     	Intratumoral                   	Combined with 5-FC and standard chemotherapy                              	NCT02414165
                          	Solid tumors             	I/II  	Recruiting             	Intratumoral Intravenous       	Combined with 5-FC                                                        	NCT02576665
                          	                         	      	                       	                               	                                                                          	
LOAd703                   	Pancreatic cancer        	I/IIa 	Recruiting             	Intratumoral                   	Combined with standard of care treatment (gemcitabine plus nab-paclitaxel)	NCT02705196
Abbreviations: 5-FC, 5-fluorocytosine; GM-CSF, granulocyte macrophage colony-stimulating factor; IFNγ, interferon γ; MAGEA3, melanoma antigen family A3; s.c., sub cutem.*initiated between 2014, March 1 and 2015, October 31.
===Approved somewhere===
*Talimogene laherparepvec was approved by the US FDA in 2015, with the brand name Imlygic, for the treatment of melanoma in patients with inoperable tumors. In Jan 2016 it was approved in Europe for some inoperable melanoma.Metastatic Melanoma Therapy, Imlygic, Now Available in EU
*Oncorine,  by Shanghai Sunway Biotech, was approved in China for Head and neck cancer in 2005. It is based on the adenovirus H101.
*RIGVIR, approved for melanoma treatment in Latvia (2004), then suspended 2019, Georgia (2015) and Armenia (2016) for melanoma treatment.
===RIGVIR section needs updates===
Article still lists Rigvir as approved somewhere, but its licence has been suspended in 2019 and in Latvian media there is talk of a criminal offence having been commited. Please see original ECHO-7 article for latest news: https://en.wikipedia.org/wiki/ECHO-7KC LV (talk) 08:18, 12 July 2019 (UTC)
thread_title:  Section "reporting" on clinical trials

message: Article still lists Rigvir as approved somewhere, but its licence has been suspended in 2019 and in Latvian media there is talk of a criminal offence having been commited. Please see original ECHO-7 article for latest news: https://en.wikipedia.org/wiki/ECHO-7KC LV (talk) 08:18, 12 July 2019 (UTC)
thread_title: RIGVIR section needs updates

message: *SEPREHVIR (HSV-1716), by Virttu Biologics completed phase I in glioblastoma, in squamous cell carcinoma of head and neck, and in melanoma. Ongoing phase I dose escalation study of intratumoral HSV-1716 in pediatric/young adult patients with non–central nervous system solid tumours and a new phase I/IIa study in mesothelioma commenced in 2012.
*CGTG-102 (Ad5/3-D24-GMCSF), by Oncos Therapeutics, while in phase I was already used to treat 200 advanced cancer patients in the company's Advanced Therapy Access Program.
*MV-NIS, an engineered measles virus has shown to be effective in targeted destruction of myeloma plasma cells. Radioactive Iodine imaging provides a novel technique for NIS gene expression monitoring.
*DNX-2401 is an oncolytic adenovirus with US Orphan drug status for glioma.
-- Jytdog (talk) 20:41, 15 June 2018 (UTC)
thread_title: Started phase I

message: Is the assessment here unbiased? The negative material appears based on a blog and news sources but a 2018 review in the European Journal of Pharmacology appears cautiously positive. Espresso Addict (talk) 03:46, 16 April 2019 (UTC)
thread_title:  Rigvir